Federal Register of Legislation - Australian Government

Primary content

PB 73 of 2020 Determinations/Health as made
This instrument amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) by adding three drugs to F1 and moves three curently listed drugs from F1 and CDL to F2. In addition, it also moves one drug from F2 to F1.
Administered by: Health
Registered 31 Jul 2020
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 73 of 2020

 

National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 7)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make the following determination.

Dated   30        July 2020                    

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 


Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010)                 2

 

 


1  Name

                   This instrument is the National Health (Listed drugs on F1 or F2) Amendment Determination 2020 (No. 7).

                   This instrument may also be cited as PB 73 of 2020.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 August 2020.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 85AB(1) and section 99AEJ of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1Amendments

National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010)

1  Schedule 1, after item dealing with Entacapone

Insert:

Entrectinib

Schedule 1, after item dealing with Lithium

Omit “Lurasidone”, substitute “Lorlatinib”.

Schedule 1, after item dealing with Mepolizumab

Insert:

Mercaptopurine

4  Schedule 1, after item dealing with Nilutamide

Omit “Nitrofurantoin”.

5  Schedule 1, after item dealing with Sterculia with frangula bark

Insert:

Stiripentol

6  Schedule 2, after item dealing with Levodopa with carbidopa

Insert:

Levodopa with carbidopa and entacapone

7  Schedule 2, after item dealing with Losartan

Insert:

Lurasidone

8  Schedule 2, after item dealing with Memantine

Omit “Mercaptopurine”.

9  Schedule 2, after item dealing with Nitrazepam

Insert:

Nitrofurantoin